Results 121 to 130 of about 7,229 (203)

Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series. [PDF]

BMC Infect Dis
Burton HJ, Rivere E, Kirk S, Berry H, Lueking R.   +4 more
europepmc   +1 more source

Implementation of Long-Acting Cabotegravir/Rilpivirine in US HIV Care Settings: Results From a National Survey of Frontline Clinicians. [PDF]

Open Forum Infect Dis
Short WR, Ogle MC, Farmer E, Kapalko A, Packett B, Riley AC, Binkley A.   +6 more
europepmc   +1 more source

Efficacy of Long-Acting Injectable Cabotegravir and Rilpivirine Compared With Daily Oral Antiretroviral Therapy in Patients With HIV: A Systematic Review. [PDF]

Cureus
Endara-Mina J, Quishpe M, Vera E, Haro N, Guzmán A, Guillin J, Quisnancela K, Sarmiento-Vallejo H, Mantilla-Alcivar I, Cabrera C, Cueva J, Serrano S, Caiza C, Intriago C, Salazar P.   +14 more
europepmc   +1 more source

Long-Acting Antiretroviral Therapy for HIV via Drop-in Community-Based Care.

JAMA Netw Open
Mehtani NJ, Matzat SJ, O'Connor KB, Cordoba L, Strieff S, Strough A, Philbin MM, Johnson MO, Gandhi M, Zevin B.   +9 more
europepmc   +1 more source

Effectiveness of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide from Rilpivirine or Other Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in Virologically Suppressed People with HIV: A Retrospective Analysis (DRIVE-SWITCH Study). [PDF]

Infect Dis Ther
Gagliardini R, Caioli A, Fusto M, Ottou S, Forbici F, Fabeni L, Maggi F, Plazzi MM, De Zottis F, Bellagamba R, Paulicelli J, Mastrorosa I, Grilli E, Pinnetti C, Mazzotta V, Caldera R, Forcina G, Antinori A.   +17 more
europepmc   +1 more source

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens. [PDF]

AIDS
Marcelin AG, Soulie C, Wirden M, Gruber J, Prata Menezes N, Lim T, Barriere G, Descamps D, Charpentier C, Calvez V.   +9 more
europepmc   +1 more source

Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study. [PDF]

Lancet HIV
Gaur AH, Baltrusaitis K, Capparelli EV, Moye JH, Yin DE, Masheto G, Buisson S, Harrington CM, Marzinke MA, Lowenthal ED, Scheckter R, Ace A, Ward S, Milligan R, Whitson K, Huang J, Cheung SYA, Best BM, Townley E, Roberts G, Kakuda TN, Birmingham E, Mathiba SR, Aurpibul L, Korutaro V, Smith C, Patel F, Moodley E, Bolton-Moore C, IMPAACT 2017 Collaborators, IMPAACT 2017 Team.   +30 more
europepmc   +1 more source

HIV update for the non-HIV specialist and general physician. [PDF]

Clin Med (Lond)
Ringshall M, Vera JH.
europepmc   +1 more source

Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort. [PDF]

J Int AIDS Soc
Llenas-García J, Arcos Rueda MDM, Calderón Hernaiz R, Pedrero Tomé R, Bisbal Pardo O, Matarranz M, Torralba M, Galindo Puerto MJ, Rodríguez A, Peñaranda Vera M, Sanjoaquín Conde I, de la Fuente Moral S, Cabello-Úbeda A, Navarro San Francisco C, Antelo Cuéllar K, Pedrosa Aragón M, Aguilera García M, Tiraboschi J, Martínez Álvarez RM, Vivancos MJ, Montero Hernández C, Bernal Morell E, Cabello-Clotet N, Morano Amado LE, Gisbert Pérez L, Sepúlveda MA, Alemán Valls MR, Sánchez Guirao AJ, Fanciulli C, Escrig C, Ferreira Pasos EM, Lucas-Dato A, García Torras S, Hidalgo Tenorio C, Estébanez M, Muelas-Fernandez M, Losa García JE, Cerezales Calviño A, Pino Díaz ME, Martínez Montes C, Arenas García V, Arnaiz de Las Revillas F, Pernas Pardavila H, Padilla S, Garcinuño Jiménez MÁ, Alonso Alonso L, Ramos Vicente N, Barragán Gallo PN, Cabo Magadan R, Del Álamo M, Egido Murciano MV, Juárez Toquero A, Romero Palacios A, Clavero Olmos M, García Navarro MDM, Sanz J, Gainzarain JC, Milian Sanz M, de la Calle B, Ferrero Benéitez OL, Troya J, Buzón-Martín L, RELATIVITY Group.   +62 more
europepmc   +1 more source

Real-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery. [PDF]

Open Forum Infect Dis
Davis JM, O'Neill J, Lyden E, Bares SH.
europepmc   +1 more source